TB-500 mimics endogenous thymosin β4, modulating inflammation and activating repair pathways including PI3K/Akt and Notch signaling to enhance angiogenesis and cell migration[1][2]. It promotes actin sequestration and is studied for accelerating wound healing, reducing fibrosis, and improving function after ischemic or traumatic injuries. BPC-157 upregulates angiogenic pathways (including VEGF) and counteracts inflammatory cytokines[3]. Preclinical research demonstrates improved healing of muscle, tendon, ligament, and bone with no observed toxicity[4][5]. The combination targets complementary mechanisms: TB-500 for systemic tissue repair signaling and BPC-157 for localized healing support.
